- Home
- WERN vs KYMR Comparison
WERN vs KYMR Comparison
Compare WERN & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WERN
- KYMR
- Stock Information
- Founded
- WERN 1956
- KYMR 2015
- Country
- WERN United States
- KYMR United States
- Employees
- WERN N/A
- KYMR N/A
- Industry
- WERN Trucking Freight/Courier Services
- KYMR Medicinal Chemicals and Botanical Products
- Sector
- WERN Industrials
- KYMR Health Care
- Exchange
- WERN Nasdaq
- KYMR Nasdaq
- Market Cap
- WERN 2.0B
- KYMR 2.2B
- IPO Year
- WERN N/A
- KYMR 2020
- Fundamental
- Price
- WERN $28.30
- KYMR $25.97
- Analyst Decision
- WERN Hold
- KYMR Buy
- Analyst Count
- WERN 15
- KYMR 13
- Target Price
- WERN $35.13
- KYMR $56.69
- AVG Volume (30 Days)
- WERN 998.0K
- KYMR 847.3K
- Earning Date
- WERN 04-29-2025
- KYMR 05-01-2025
- Dividend Yield
- WERN 1.98%
- KYMR N/A
- EPS Growth
- WERN N/A
- KYMR N/A
- EPS
- WERN 0.55
- KYMR N/A
- Revenue
- WERN $3,030,258,000.00
- KYMR $47,072,000.00
- Revenue This Year
- WERN $3.79
- KYMR $16.24
- Revenue Next Year
- WERN $7.34
- KYMR $22.41
- P/E Ratio
- WERN $51.63
- KYMR N/A
- Revenue Growth
- WERN N/A
- KYMR N/A
- 52 Week Low
- WERN $26.50
- KYMR $19.45
- 52 Week High
- WERN $42.48
- KYMR $53.27
- Technical
- Relative Strength Index (RSI)
- WERN 43.41
- KYMR 44.70
- Support Level
- WERN $27.13
- KYMR $24.43
- Resistance Level
- WERN $29.07
- KYMR $26.06
- Average True Range (ATR)
- WERN 1.40
- KYMR 2.36
- MACD
- WERN 0.11
- KYMR 0.41
- Stochastic Oscillator
- WERN 49.72
- KYMR 70.12
About WERN Werner Enterprises Inc.
Werner Enterprises Inc is a transportation and logistics company. The company has two reportable segments - TTS and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.